Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future.
Chronic liver disease and hepatocellular carcinoma associated with chronic hepatitis B virus (HBV)-infection are among the most serious human health problems in highly endemic regions. Current therapeutic approaches to control chronic hepatitis such as interferon-alpha and lamivudine are unsatisfactory. Vaccination would be the therapeutic procedure with the lowest cost and the potentially greatest benefit. The immunogenicity of selected HBV envelope- or capsid-based vaccine formulations for the induction or the broadening of T and B cell responses, deficient in HBV chronic carriers, are currently under study in animal models and in clinical trials.
Michel
M L
ML
Unité de Recombinaison et Expression Génétique, INSERM U 163, Institut Pasteur, 75724 Cédex 15, Paris, France. maloum@pasteur.fr
Pol
S
S
Brechot
C
C
Tiollais
P
P
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology; D019444:Vaccines, DNA / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic